Vivos Therapeutics (NASDAQ:VVOS) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Vivos Therapeutics (NASDAQ:VVOSGet Rating) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

Separately, Craig Hallum cut their price objective on shares of Vivos Therapeutics to $5.00 and set a na rating on the stock in a research report on Tuesday, May 17th.

NASDAQ VVOS opened at $1.87 on Wednesday. The firm’s fifty day simple moving average is $1.90 and its 200-day simple moving average is $2.40. The company has a market capitalization of $43.03 million, a PE ratio of -1.78 and a beta of 0.83. Vivos Therapeutics has a 1-year low of $1.18 and a 1-year high of $7.09.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. increased its stake in Vivos Therapeutics by 60.0% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock valued at $43,000 after buying an additional 7,200 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Vivos Therapeutics in the 1st quarter valued at $29,000. Perkins Capital Management Inc. increased its stake in Vivos Therapeutics by 10.3% in the 1st quarter. Perkins Capital Management Inc. now owns 150,050 shares of the company’s stock valued at $402,000 after buying an additional 14,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in Vivos Therapeutics in the 3rd quarter valued at $60,000. Finally, National Asset Management Inc. increased its stake in Vivos Therapeutics by 46.9% in the 3rd quarter. National Asset Management Inc. now owns 50,987 shares of the company’s stock valued at $206,000 after buying an additional 16,269 shares during the last quarter. 9.81% of the stock is currently owned by institutional investors and hedge funds.

Vivos Therapeutics Company Profile (Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Further Reading

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.